Clinical Trials Logo

Clinical Trial Summary

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week 52, and to assess the safety and tolerability of upadacitinib in participants with giant cell arteritis (GCA). The objective of period 2 is to evaluate the safety and efficacy of continuing versus withdrawing upadacitinib in maintaining remission in participants who achieved sustained remission in Period 1.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03725202
Study type Interventional
Source AbbVie
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 24, 2019
Completion date March 3, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04930094 - Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) Phase 3
Recruiting NCT05479448 - Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis